Results 11 to 20 of about 1,460,729 (292)
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
EMBO Molecular Medicine, 2018 Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways.James W Peacock, Ario Takeuchi, Norihiro Hayashi, Liangliang Liu, Kevin J Tam, Nader Al Nakouzi, Nastaran Khazamipour, Tabitha Tombe, Takashi Dejima, Kevin CK Lee, Masaki Shiota, Daksh Thaper, Wilson CW Lee, Daniel HF Hui, Hidetoshi Kuruma, Larissa Ivanova, Parvin Yenki, Ivy ZF Jiao, Shahram Khosravi, Alice L‐F Mui, Ladan Fazli, Amina Zoubeidi, Mads Daugaard, Martin E Gleave, Christopher J Ong +24 moredoaj +1 more sourceThe relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer
BMC Urology, 2023 Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson +13 moredoaj +1 more sourceTOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. [PDF]
, 2017 Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated ...Alshalalfa, Mohammed, Bowden, Michaela, Brown, Myles, Davicioni, Elai, Den, Robert B., Ellis, Leigh, Eng, Kevin H., Erho, Nicholas, Feng, Felix Y., Galbo, Phillip, Goodrich, David W., Gray, Kathryn P., Huang, Ying, Jenkins, Robert B., Karnes, R. Jeffrey, Ku, Sheng-Yu, Labbé, David P., Rosario, Spencer, Ross, Ashley E., Schaeffer, Edward M., Sjöström, Martin, Spratt, Daniel E., Sweeney, Christopher J., Wadosky, Kristine M. +23 morecore +2 more sourcesInitial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
The World Journal of Men's Health, 2023 Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need
to optimize practices to better risk-stratify patients.Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik +15 moredoaj +1 more sourceCylindrical illumination with angular coupling for whole-prostate photoacoustic tomography [PDF]
, 2019 Current diagnosis of prostate cancer relies on histological analysis of tissue samples acquired by biopsy, which could benefit from real-time identification of suspicious lesions.Bungart, Brittani, Cao, Yingchun, Cheng, Ji-Xin, Cheng, Liang, Gorsky, Sean, Koch, Michael O., Lan, Lu, Masterson, Timothy, Roblyer, Darren, Yang-Tran, Tiffany +9 morecore +1 more sourceCellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma
Neoplasia: An International Journal for Oncology Research, 2015 Vascular endothelial growth factor (VEGF)–targeted antiangiogenic therapy significantly inhibits the growth of clear cell renal cell carcinoma (RCC).Kyung Seok Han, Peter A. Raven, Sebastian Frees, Kilian Gust, Ladan Fazli, Susan Ettinger, Sung Joon Hong, Cristian Kollmannsberger, Martin E. Gleave, Alan I. So +9 moredoaj +1 more sourceSmall extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biology & Therapy, 2022 The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino +10 moredoaj +1 more sourceHedgehog Signalling in Androgen Independent Prostate Cancer [PDF]
, 2008 Objectives: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis.Bisson, Isabelle, Ktori, Elena, McFaul, Siobhan, Oliver, R. Tim D, Price, Anna M., Prowse, David M., Purkis, Patricia E., Shaw, Greg +7 morecore +1 more sourceAge and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. [PDF]
, 2016 A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility.Karnes, R Jeffrey, Kattan, Michael W, MacKintosh, F Roy, Morrell, Christopher H, Nawaf, Cayce B, Neville, Thomas B, Rawson, Lori, Sprenkle, Preston C, Walter, Louise C +8 morecore +1 more sourceWNT signalling in prostate cancer [PDF]
, 2017 Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine +166 morecore +2 more sources
